27 November, Melbourne, Australia – Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot, has been granted in China.

China is the latest in a growing list of countries where the patent has now been granted which include the EU, Japan and Australia.

Michael Grant, CEO of Q-Sera, says, “China is a growing market for biochemistry testing tubes and a major interest for companies in the tube manufacturing sector including local, regional and global companies. Q-Sera tubes will allow rapid expansion into this growing market and bring benefits to a wide range of patients.”

The scientific data behind Q-Sera’s ground-breaking blood clotting technology, recombinant prothrombin activator RAPClot, was recently presented in Durban at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine, IFCC Worldlab 2017, with further clinical data recently submitted for publication.

By isolating proteins found in the venom of some of the world’s deadliest snakes in Australia and others from overseas, Q-Sera has developed a novel class of coagulation agents patented for use in blood collection tubes. These ‘prothrombin activators’ were initially sourced from snake venom but can now be produced from modified cell lines using standard pharmaceutical manufacturing processes.

Blood collection tubes are coated with RAPClot, resulting in tubes which rapidly produce high quality serum, even if the blood sample contains anti-coagulants. These benefits may translate into cost efficiencies and reductions for healthcare systems and improved outcomes for patients.

Q-Sera is actively commercialising its disruptive technology and is currently working with a number of multinational medical device companies to bring this technology and its benefits to market.

 

Media enquiries:
Andrew Hamilton +61420 447 669 or ah@manacommunications.com

 

About Q-Sera Pty Ltd:
Q-Sera is a registered company founded to commercialise intellectual property developed at the University of Queensland (UQ) and licensed by UniQuest which details active proteins and formulations for a new type of serum collection tube. The technology behind Q-Sera involves using a certain class of proteins (prothrombin activators) originally identified from the venom of specific snakes to accelerate the clotting of blood in an improved blood collection tube to produce high quality serum for biochemical analysis. The company has developed two actives, one naturally sourced from snake venom and one a recombinantly manufactured protein (RAPClot). Prototype tubes have been manufactured and proof-of-concept studies completed, demonstrating the superiority of the Q-Sera tube compared to the current commercial tubes in clotting blood and producing high quality serum for pathology testing from healthy and anti-coagulated patients.

For more information visit: www.q-sera.com

 

About Uniseed:
Uniseed is a venture fund operating at the Universities of Melbourne, Queensland, New South Wales and Sydney, as well as the CSIRO. Uniseed’s mandate is to facilitate the commercialisation of research partner generated intellectual property by targeted investment in highly promising technologies. Uniseed’s investments cover a range of technology sectors. For more information, go to www.uniseed.com